PADAGIS US
GenericsPADAGIS US is a generic drug manufacturer focused on Dermatology, Infectious Disease, Cardiovascular.
PADAGIS US at a Glance
- Strong track record with 100% execution quality across 21 trials
- Fast trial execution (10 months median completion)
PADAGIS US's Key Drugs
PADAGIS US's core commercial portfolio centers on BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, spanning Dermatology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
PADAGIS US's Recent FDA Approvals
New NDA/BLA approvals for PADAGIS US over the last two years — novel drugs only, excluding generics and label supplements.
PADAGIS US's Therapeutic Areas
PADAGIS US's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Infectious Disease, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PADAGIS US's Top Competitors
PADAGIS US's closest competitors by therapeutic-area and drug-target overlap include Baxter, FOUGERA PHARMS, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PADAGIS US Pipeline Snapshot
Active clinical trials for PADAGIS US across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 21/21 completed
- • Speed: 10 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (2)
Company Info
- First Approval
- 1971-11-09
- Latest
- 2026-06-18
- Applications
- 93
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges